Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival.

"all data were de-identified and collected retrospectively from each center. table s1"

"CONFLICT OF INTEREST STATEMENT Alexandre de Nonneville declares Consulting fees by Gilead, Seagen, Lilly, and Novartis, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events by Gilead, Daiichi Sankyo, and MSD, Support for attending meetings and/or travel by Gilead, Lilly, and Daiichi Sankyo. Emmanuelle Charaffe declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events by Exact Science (to institution), Veracyte (to institution), and AstraZeneca. Anthony Gonçalves declares Support for attending meetings and/or travel by Menarini, Participation on a Data Safety Monitoring Board or Advisory Board by Novartis, MSD, and Daiichi Sankyo. No conflict of interest was declared by others authors."

"FUNDING INFORMATION This academic work did not receive financial support from any funding source."